NCT06390111 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06390111
Title	A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose. (ABLE-42)
Acronym	ABLE-42
Recruitment	Withdrawn
Gender	both
Phase	Expanded access
Variant Requirements	No
Sponsors	Ferring Pharmaceuticals
Indications	bladder carcinoma in situ non-invasive bladder urothelial carcinoma
Therapies	Nadofaragene firadenovec
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Ferring Investigational Site		Little Rock	Arkansas	72211	United States	Details
Ferring Investigational Site		Atlanta	Georgia	30328	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT06390111Clinical Trial Detail